Clinical trials: Glioma
Diffuse Midline Glioma, H3 K27M-Mutant
Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma
This phase I, first-in-human trial tests the safety, side effects, and best dose of genetically modified cells called KIND T cells after lymphodepletion (a short dose of chemotherapy) in treating patients who are…
- Trial name
- PNOC018 (NCT05478837)
- Testing
- Cyclophosphamide, Fludarabine, Autologous Anti-H3.3K27M TCR-expressing T-cells
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of California, San Francisco
Brain Tumor, Brain Neoplasms
Brain Tumor Intraoperative Ultrasound Database
Predicting the survival of patients diagnosed with glioblastoma (GBM) is essential to guide surgical strategy and subsequent adjuvant therapies.
- Conditions
- Brain Tumor, Brain Neoplasms, Brain Cancer, Glioma
- Trial name
- BraTioUS-DB (NCT05062772)
- Testing
- Ultrasound
- Where
- 6 sites in United States, France and 3 more
- Volunteers
- 150 people
- Sponsor
- Hospital del Rio Hortega
Refractory Cancer, Refractory Neoplasm
9-ING-41 in Pediatric Patients With Refractory Malignancies.
9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients. This Phase 1 study will study its efficacy in paediatric patients with advanced malignancies.
- Conditions
- Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor
- Trial name
- NCT04239092
- Testing
- 9-ING-41, Irinotecan, Temozolomide
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Actuate Therapeutics Inc.
Glioma, Brain Cancer
Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
DC vaccine manufactured and partially matured using our standard operating procedures, developed in collaboration with the HGG Immuno Group, then administered through imiquimod treated skin will be safe and feasible in children…
- Conditions
- Glioma, Brain Cancer, Brain Tumor, Glioblastoma Multiforme
- Trial name
- NCT01902771
- Testing
- Dendritic Cell Vaccine, Tumor Lysate, Imiquimod
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Edward Ziga
Ependymoma
Carboplatin as a Radiosensitizer in Treating Childhood Ependymoma
This is a phase II study evaluating the feasibility of concurrent carboplatin given with focal radiation therapy in children age 12 months to < 21 years with newly diagnosed localized ependymoma who have no or minimal residual…
- Trial name
- NCT01088035
- Testing
- Carboplatin
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in…
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT07440290)
- Testing
- Dabrafenib, Trametinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Brain Tumor, Central Nervous System Tumor
Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00006024
- Testing
- lomustine, temozolomide
- Where
- 235 sites in United States, Australia and 5 more
- Volunteers
- 32 people
- Sponsor
- Children's Oncology Group
Neuroendocrine Tumors, Carcinoid Tumors
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
Participants in this study have been diagnosed with a tumor such as a carcinoid, neuroendocrine tumor, neuroblastoma, Ewing's sarcoma, or brain tumor that has cells which carry somatostatin receptors.
- Conditions
- Neuroendocrine Tumors, Carcinoid Tumors, Neuroblastoma, Medulloblastoma
- Trial name
- NCT02441062
- Testing
- 68Ga-DOTATOC PET/CT
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- Sue O'Dorisio
Brain Stem Glioma
Effect of Antineoplaston Therapy on the QT/QTc Interval In Subjects With Diffuse, Intrinsic, Brainstem Glioma
The primary objective of this protocol study is to investigate the effect of Antineoplaston therapy on the QT/QTc interval in study subjects age 3 to 21 years with newly-diagnosed, diffuse, intrinsic brainstem glioma.
- Trial name
- DBSG (NCT02864888)
- Testing
- Radiation, Atengenal, Astugenal
- Volunteers
- 30 people
- Sponsor
- Burzynski Research Institute
Brain Stem Neoplasms, Glioma
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Background: IMC-A12 is an experimental substance designed to inhibit a protein called Type I Insulin-Like Growth Factor Receptor (IGF-1R), which can be found on cancer cells and can promote cancer growth.
- Conditions
- Brain Stem Neoplasms, Glioma, Pinealoma
- Trial name
- NCT01182883
- Testing
- IMC-A12, Temsirolimus
- Sponsor
- National Cancer Institute (NCI)
Recurrent Childhood Ependymoma
Everolimus for Children With Recurrent or Progressive Ependymoma
The purpose of this study is to evaluate the anti-tumor activity of Everolimus among children with recurrent or progressive ependymoma. Recurrent or progressive ependymoma is incurable and has very limited treatment options.
- Trial name
- NCT02155920
- Testing
- Everolimus
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- University of Texas Southwestern Medical Center
Neurofibromatosis Type 1
Ophthalmological Screening and Follow-up of Optic Pathway Gliomas in Children With Neurofibromatosis Type 1.
The goal of this project is to get more insight into the (neuro)ophthalmological characteristics of children with neurofibromatosis type 1.
- Trial name
- NCT02078401
- Where
- Belgium
- Volunteers
- 200 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Brain and Central Nervous System Tumors, Sarcoma
High-Dose Methotrexate in Treating Young Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as high-dose methotrexate work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00513981
- Testing
- leucovorin calcium, methotrexate, mass spectrometry
- Where
- 21 sites in Ireland, United Kingdom
- Volunteers
- 36 people
- Sponsor
- Children's Cancer and Leukaemia Group
Neuroendocrine Tumors, Carcinoid Tumors
Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors
This protocol is designed to test the efficacy of 68Ga-DOTATOC PET/CT in diagnosis, staging, and measurement of response to treatment in patients with somatostatin receptor positive tumors.
- Conditions
- Neuroendocrine Tumors, Carcinoid Tumors, Neuroblastoma, Medulloblastoma
- Trial name
- GA-68 (NCT01619865)
- Testing
- 68Ga-DOTATOC PET/CT
- Where
- United States
- Volunteers
- 223 people
- Sponsor
- Sue O'Dorisio
Glioma, Malignant, Glioma, Mixed
Clinical Evaluation of Genetron IDH1 PCR Kit in Glioma Patients
The purpose of this trail is to evaluate the performance of Genetron IDH1 PCR Kit in Glioma patients using real-time PCR method.
- Trial name
- NCT05100173
- Where
- 4 sites in China
- Volunteers
- 1,192 people
- Sponsor
- Genetron Health
Brain Tumor, Cancer
000860: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
Protocol # 000860 Background: Diffuse gliomas are tumors that affect the brain and spinal cord. Gliomas that develop in people with certain gene mutations (IDH1 or IDH2) are especially aggressive. Better treatments are needed.
- Trial name
- NCT05588141
- Testing
- Zotiraciclib
- Where
- 2 sites in United States
- Volunteers
- 96 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Lobradimil and Carboplatin in Treating Children With Brain Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Lobradimil may increase the effectiveness of a chemotherapy drug by making tumor cells more sensitive to the…
- Trial name
- NCT00019422
- Testing
- carboplatin, lobradimil
- Where
- 236 sites in United States, Australia and 5 more
- Sponsor
- National Cancer Institute (NCI)
Recurrent and Refractory Solid Tumors
Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
Phase 1 of this study, utilizing a rolling 6 design, will be conducted to determine a maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), and to describe the toxicities of lenvatinib administered in combination with…
- Trial name
- NCT03245151
- Testing
- Lenvatinib, Everolimus
- Where
- 50 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- Eisai Inc.
Lymphoma, Childhood Lymphoma
Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)
Toxicities related to pediatric cancer treatment can lead to significant illness, organ damage, treatment delays, increased health care cost, and decrease in quality of life.
- Conditions
- Lymphoma, Childhood Lymphoma, Solid Tumor, Childhood Solid Tumor
- Trial name
- UVA-Gen001 (NCT02624388)
- Testing
- Genistein
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Virginia
Melanoma, Solid Tumor
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
This is a subprotocol of Master Protocol DAY101-102 and is a Phase 1b/2, multi-center, open label subprotocol of participants ≥12 years of age, with recurrent or progressive solid tumors with alterations in the key proteins of…
- Conditions
- Melanoma, Solid Tumor, Pilocytic Astrocytoma, Non Small Cell Lung Cancer
- Trial name
- NCT07121829
- Testing
- Tovorafenib, Tovorafenib Drug: Pimasertib
- Where
- 10 sites in United States, Canada
- Volunteers
- 44 people
- Sponsor
- Day One Biopharmaceuticals, Inc.